Abiomed - ABMD Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Abiomed in the last twelve months. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ABMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABMD, but not buy additional shares or sell existing shares.
View ABMD analyst ratings or view top-rated stocks.

7 equities research analysts have issued 12 month target prices for Abiomed's stock. Their ABMD share price forecasts range from $300.00 to $388.00. On average, they anticipate the company's stock price to reach $350.50 in the next year. This suggests that the stock has a possible downside of 8.0%.
View analysts price targets for ABMD or view top-rated stocks among Wall Street analysts.

Abiomed's stock was trading at $381.02 at the beginning of 2023. Since then, ABMD shares have increased by 0.0% and is now trading at $381.02.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023.
View our ABMD earnings forecast.

Abiomed, Inc. (NASDAQ:ABMD) announced its quarterly earnings results on Wednesday, October, 27th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $0.98 by $0.05. The medical equipment provider earned $248.10 million during the quarter, compared to analyst estimates of $248.06 million. Abiomed had a net margin of 24.84% and a trailing twelve-month return on equity of 14.77%. Abiomed's revenue for the quarter was up 18.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.01 earnings per share.
Read the conference call transcript.

96 employees have rated Abiomed Chief Executive Officer Michael R. Minogue on Glassdoor.com. Michael R. Minogue has an approval rating of 72% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Abiomed investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Intuitive Surgical (ISRG), Block (SQ), Netflix (NFLX), Adobe (ADBE) and Salesforce (CRM).

Abiomed trades on the NASDAQ under the ticker symbol "ABMD."

Abiomed's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Ronald Blue Trust Inc. (0.01%), Baillie Gifford & Co. (0.01%), DekaBank Deutsche Girozentrale (0.00%), FNY Investment Advisers LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Joseph Riccelli, Magdalena Yesil, Marc A Began, Martin P Sutter, Matthew T Plano, Michael R Minogue, Michael R Minogue, Paul Thomas and Todd A Trapp.
View institutional ownership trends.

Shares of ABMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABMD stock can currently be purchased for approximately $381.02.

Abiomed (NASDAQ:ABMD) has a market capitalization of $17.18 billion and generates $1.03 billion in revenue each year. The medical equipment provider earns $136.51 million in net income (profit) each year or $5.82 on an earnings per share basis.

The company employs 2,003 workers across the globe.

Abiomed's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The official website for the company is www.abiomed.com. The medical equipment provider can be reached via phone at (978) 646-1400, via email at ir@abiomed.com, or via fax at 978-777-8411.